Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

BACKGROUND: The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Zezza, Marco, Kosinski, Christophe, Mekoguem, Carine, Marino, Laura, Chtioui, Haithem, Pitteloud, Nelly, Lamine, Faiza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929418/
https://www.ncbi.nlm.nih.gov/pubmed/31870373
http://dx.doi.org/10.1186/s12902-019-0467-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929418/
https://www.ncbi.nlm.nih.gov/pubmed/31870373
http://dx.doi.org/10.1186/s12902-019-0467-z

Ejemplares similares